Calvin Perumalla

Title: Innovations by Calvin Perumalla in Cardiac Monitoring

Introduction

Calvin Perumalla is an accomplished inventor based in Tampa, FL (US). He has made significant contributions to the field of cardiac monitoring through his innovative patents. With a focus on improving patient care, his work has the potential to enhance the prediction and management of atrial fibrillation.

Latest Patents

Calvin Perumalla holds two notable patents. The first is a "System and method for the prediction of atrial fibrillation (AF)." This invention provides patient-specific models to distinguish between electrocardiogram (ECG) epochs that are far from atrial fibrillation rhythms and those that are just prior to the onset of AF episodes. This predictive capability is crucial for timely intervention in patients at risk of AF. The second patent is for an "Integrated vectorcardiogram system and method of use." This device features three pairs of electrodes arranged in orthogonal directions, allowing for continuous measurement of the heart's electrical activity. The miniaturized housing of the device eliminates the cumbersome wires associated with traditional 12-lead ECG systems while maintaining the same quality of information. Additionally, the integrated VCG device can wirelessly transmit data to remote devices, facilitating real-time patient monitoring.

Career Highlights

Calvin Perumalla is affiliated with the University of South Florida, where he continues to advance his research and innovations in cardiac health. His work is instrumental in bridging the gap between technology and patient care, making significant strides in the medical field.

Collaborations

Calvin has collaborated with notable colleagues, including Richard Dennis Gitlin and Gabriel Eduardo Arrobo. These partnerships have fostered a collaborative environment that enhances the development of innovative solutions in cardiac monitoring.

Conclusion

Calvin Perumalla's contributions to the field of cardiac monitoring through his patents demonstrate his commitment to improving patient outcomes. His innovative approaches have the potential to revolutionize how atrial fibrillation is predicted and managed, ultimately benefiting countless patients.